한글목차

불활화 백신의 동향과 예측

세계 불활화 백신 시장은 2024년부터 2030년까지의 CAGR이 5.4%로 예상되며, 2030년까지 추정 545억 달러에 이를 것으로 예상됩니다. 시장 촉진 요인에는 백신에 대한 수요가 증가하고 예방 접종을 촉진하기위한 정부의 적극적인 노력, 전염병의 유행 증가가 있습니다.

• Lucintel의 예측에 의하면, 유형별로는 바이러스 감염 예방에 유효한 불활화 백신 수요가 크기 때문에 바이러스성 백신이 예측 기간 중에 높은 성장을 이룰 전망입니다.
• 최종 용도 범주에서는 병원이 예측 기간 동안 가장 높은 성장을 보일 것으로 예상됩니다.
• 지역별로는 아시아태평양이 예측기간 중에 가장 높은 성장이 예상됩니다.

불활화 백신 시장의 전략적 성장 기회

불활화 백신 시장 시장 분석은 다양한 응용 분야에서 성장 기회를 확인하고 있습니다.

• 신흥 감염에 대한 불활화 백신의 가능성: 신흥 감염에 대한 불활화 백신의 개발은 성장을 가속할 것으로 예상됩니다.
• 만성 질환 관리에서 불활화 백신의 가능성 : 불활화 백신은 암과 당뇨병과 같은 만성 질환의 관리를 위해 연구되었습니다.
• 소아 백신 접종의 불활화 백신의 가능성: 소아용 불활화 백신의 선택을 넓히는 것으로, 추가 성장 기회가 있습니다.
• 여행 및 관광 분야에 있어서의 불활화 백신의 가능성: 여행 관련 질환에 대한 불활화 백신 수요가 높아지고 있습니다. 해외 여행의 재개에 수반해, 현지의 풍토병으로부터 사람들을 지키는 백신에의 요구가 높아지고 있습니다.
• 생물 방어에서의 불활화 백신의 가능성 : 바이오 테러 방어를 위한 불활화 백신 개발에 대한 관심도 높아지고 있습니다.

이러한 성장 기회는 불활화 백신의 폭넓은 용도를 명확히 하고, 그 시장성을 높여, 헬스케어 시스템의 진보나 기술 개량의 원동력이 되고 있습니다.

불활화 백신 시장 성장 촉진요인·과제

불활화 백신 시장은 기술적·경제적·규제적 요인을 포함한 다양한 시장 성장 촉진요인·과제의 영향을 받고 있습니다.이러한 요인을 이해하는 것이, 시장 역학을 인식하는 열쇠가 됩니다.

불활화 백신 시장을 견인하는 요인은 다음과 같습니다.

• 기술 진보 : 새로운 보조제 및 기타 제제와 같은 백신 제조의 최근 기술 혁신은 시장을 밀어 올리고 있습니다.
• 백신 수요 증가: 전염병의 이환율의 상승이나 보건 기관에 의한 캠페인이 불활화 백신 수요를 촉진하고 있습니다.
• 규제 지원 : 백신 승인 및 시장 진입에는 좋은 규제 환경이 필수적입니다. 효율적인 규제나 가이드라인은 지연을 없애고 새로운 불활화 백신이 더욱 효율적으로 시장에 투입되게 합니다.
• 건강 관리 인프라 개선 : 보관 및 유통 시스템과 같은 건강 관리 인프라를 강화하면 불활화 백신을보다 효과적으로 투여하는 데 도움이 됩니다. 지리적으로 충분히 서비스를 받지 못하는 지역에 도달하기 위해 매우 중요합니다.
• 연구개발에 대한 투자: 연구개발에 대한 투자확대에 의해 백신의 유효성이 혁신되고 있습니다.

불활화 백신 시장의 과제는 다음과 같습니다.

• 높은 제조 비용 : 비 생존 백신의 개발 및 제조에는 여전히 비용이 듭니다.
• 시장 경쟁 : 백신 제조업체 간의 격렬한 경쟁이 가격 하락의 압력이되고 있으며, 각 회사는 경쟁력을 유지하기 위해 제품의 지속적인 갱신을 강요하고 있습니다.

불활화 백신 시장은 기술의 진보, 수요 증가, 지지적인 규제 틀과 같은 중요한 촉진요인 이외에, 컴플라이언스, 제조 비용, 경쟁에 관한 과제에 의해 형성되고 있습니다. 개척과 역학에서 매우 중요합니다.

목차

제1장 주요 요약

제2장 세계의 불활화 백신 시장 : 시장 역학

• 소개, 배경, 분류
• 공급망
• 업계의 촉진요인과 과제

제3장 시장 동향과 예측 분석(2018-2030년)

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 불활화 백신 시장 동향(2018-2023년)과 예측(2024-2030년)
• 유형별 : 불활화 백신 세계 시장
  • 바이러스
  • 박테리아
  • 기타
• 최종 용도별 : 불활화 백신 세계 시장
  • 병원
  • 재택 케어
  • 전문 클리닉
  • 기타

제4장 지역별 시장 동향과 예측 분석(2018-2023년)

• 지역별 불활화 백신 세계 시장
• 북미 불활화 백신 시장
• 유럽 불활화 백신 시장
• 아시아태평양의 불활화 백신 시장
• 기타 지역의 불활화 백신 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 유형별 세계 불활화 백신 시장의 성장 기회
  • 최종 용도별 세계 불활화 백신 시장의 성장 기회
  • 지역별 세계의 불활화 백신 시장의 성장 기회
• 세계 불활화 백신 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 세계 불활화 백신 시장의 생산 능력 확대
  • 세계의 불활화 백신 시장에서의 합병, 인수, 합작 사업
  • 인증 및 라이선싱

제7장 주요 기업의 기업 프로파일

• Pfizer
• Sanofi
• GlaxoSmithKline
• Merck
• AstraZeneca
• Johnson & Johnson
• CSL Behring

영문목차

Inactivated Vaccine Trends and Forecast

The future of the global inactivated vaccine market looks promising with opportunities in the hospital, home care, and specialty clinic markets. The global inactivated vaccine market is expected to reach an estimated $54.5 billion by 2030 with a CAGR of 5.4% from 2024 to 2030. The major drivers for this market are the rising demand for more convenient and effective vaccines, supportive government initiatives to promote vaccination, and the increasing prevalence of infectious diseases.

• Lucintel forecasts that, within the type category, viral is expected to witness higher growth over the forecast period due to significant demand for inactivated vaccines given to their effectiveness at preventing viral infections.
• Within the end-use category, the hospital is expected to witness the highest growth over the forecast period due to the increasing number of inactivated vaccinations being administered to children in this facility as part of their regular immunization program.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to the augmenting cases of infectious diseases and the presence of key players in the region.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Inactivated Vaccine Market

Certain key trends can be observed in the inactivated vaccine market that are shaping the industry. These trends show improvements in technology, transformations in health needs, and changes in the regulatory environment.

• Emerging Trends in Adjuvant Technology: New adjuvants are being added to existing inactivated vaccines to improve the immune response. These developments are important for enhancing vaccines and providing wider coverage against evolving pathogens.
• Increasing Focus on Vaccine Accessibility: There is an increasing trend to provide inactivated vaccines to all parts of the world, particularly underprivileged countries. This includes actions to increase production and distribution to ensure fair provision of vital vaccines.
• Combination Vaccines: Combination inactivated vaccines for several diseases are becoming more popular. These vaccines help economize immunization schedules and improve patient adherence by reducing the number of doses.
• Incorporation of Digital Health Tools: Monitoring tools, such as tracking apps and digital vaccination records, are being incorporated with inactivated vaccines. These tools help track vaccine placement and improve patient management.
• Stronger Focus on R&D: There is a higher demand for investment in research and development of inactivated vaccines. This trend is driven by the emergence of novel infectious diseases and the need to improve currently available vaccines.

These trends are driving innovation, expanding the role of vaccines, and increasing the efficacy of inactivated vaccines, shaping the future of global vaccination programs.

Recent Developments in the Inactivated Vaccine Market

The inactivated vaccine market has undergone significant changes, indicating advancements in combating diseases with vaccines.

• Expanding the Inactivated Vaccine Pipeline: Recent approvals for inactivated vaccines targeting new pathogens have expanded the market. These vaccines have a better safety profile and address unmet medical needs.
• Streamlined Manufacturing Methods: New production technologies are enabling the efficient manufacture of inactivated vaccines. These innovations help lower prices and make vaccines more accessible, especially in marginalized areas.
• Application of New Quality Vaccine Adjuvants: Efforts are underway to develop new adjuvants that are more efficient and stable than previous ones. These changes are expected to enhance immune memory and reduce the need for boosting.
• Improvement of Distribution Channels: Efforts have increased the distribution of inactivated vaccines globally. Improved logistics and collaborations are enabling vaccines to reach distant and underserved populations.
• Raising Public Health Administration: Public health efforts by governments and organizations are increasing to promote vaccination. These initiatives include education and outreach campaigns alongside immunization efforts to boost vaccine uptake.

These developments enhance the potency of vaccines, lower development costs, and increase accessibility, fostering progress and efficiency in the inactivated vaccine market.

Strategic Growth Opportunities for Inactivated Vaccine Market

Market analysis of the inactivated vaccine market identifies growth opportunities in various application areas. These prospects reflect changing trends in global health and improvements in vaccinations.

• Potential of Inactivated Vaccines for Emerging Infectious Diseases: Developing inactivated vaccines for emerging infectious diseases is expected to drive growth. The fight against new pathogens is critical for national health security and market expansion.
• Potential of Inactivated Vaccines for Chronic Disease Management: Inactivated vaccines are being studied for managing chronic conditions like cancer and diabetes. This application offers opportunities for developing new vaccines and therapeutic agents.
• Potential of Inactivated Vaccines in Pediatric Vaccination: There are additional growth opportunities by expanding inactivated vaccine options for children. These vaccines address specific needs in children, improving immunization and disease prevention.
• Potential of Inactivated Vaccines in Travel and Tourism: There is growing demand for inactivated vaccines for travel-related diseases. As international travel resumes, there is an increased need for vaccines that protect populations from local endemic diseases.
• Potential of Inactivated Vaccines in Biodefense: There is also growing interest in developing inactivated vaccines for bioterrorism defense. These vaccines are vital for combating bioterrorism and protecting society.

These growth opportunities define the wide range of applications for inactivated vaccines, enhancing their marketability and driving progress in healthcare systems and technological improvements.

Inactivated Vaccine Market Driver and Challenges

The market for inactivated vaccines is influenced by a variety of drivers and challenges, including technological, economic, and regulatory factors. Understanding these factors is key to recognizing market dynamics.

The factors driving the inactivated vaccine market include:

• Technological Advancements: Recent innovations in vaccine manufacturing, such as new adjuvants and other formulations, are boosting the market. These improvements offer advantages in efficiency and safety, making vaccines more favorable for both patients and healthcare providers.
• Increased Demand for Vaccines: The rising incidence of communicable diseases and campaigns by health organizations are fueling demand for inactivated vaccines. This trend presents opportunities for market expansion and increased funding for vaccine development.
• Regulatory Support: A favorable regulatory environment is essential for the approval and market entry of vaccines. Effective regulations and guidelines help eliminate delays, allowing new inactivated vaccines to reach the market more efficiently.
• Healthcare Infrastructure Improvements: Enhancements in healthcare infrastructure, such as storage and distribution systems, help administer inactivated vaccines more effectively. This network is crucial for reaching geographically underserved areas.
• Investment in R&D: Increased investment in research and development is driving innovation in vaccine efficacy. Ongoing investigations into vaccine formulations are addressing the needs of new diseases.

Challenges in the inactivated vaccine market include:

• High Production Costs: Non-live vaccines remain expensive to develop and manufacture. These high costs can impact pricing and accessibility, especially in low-income areas.
• Market Competition: Intense competition among vaccine manufacturers is exerting downward pressure on prices and forcing companies to continuously update their products to remain competitive.

The inactivated vaccine market is shaped by significant drivers, such as technological advances, rising demand, and supportive regulatory frameworks, as well as challenges related to compliance, production costs, and competition. The role of these factors is crucial in the development and dynamics of the market.

List of Inactivated Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies inactivated vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the inactivated vaccine companies profiled in this report include-

• Pfizer
• Sanofi
• GlaxoSmithKline
• Merck
• Astrazeneca
• Johnson & Johnson
• CSL Behring

Inactivated Vaccine by Segment

The study includes a forecast for the global inactivated vaccine by type, end use, and region.

Inactivated Vaccine Market by Type [Analysis by Value from 2018 to 2030]:

• Viral
• Bacterial
• Others

Inactivated Vaccine Market by End Use [Analysis by Value from 2018 to 2030]:

• Hospitals
• Homecare
• Specialty Clinics
• Others

Inactivated Vaccine Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Inactivated Vaccine Market

The inactivated vaccine market has made significant progress due to continuous research, policy changes, and global health interest. This is particularly true in countries like the USA, China, India, Germany, and Japan, which share a common goal of improving vaccine safety, efficacy, and availability.

• United States: Recent updates in the U.S. include the approval of new inactivated vaccines to address gaps in immunization for emerging infectious diseases. These vaccines are designed to be more efficient, safer, and cost-effective to manufacture.
• China: China has made significant strides in developing inactivated vaccines for COVID-19 and other infectious diseases. The country is increasing production and enhancing distribution to meet both national and global demands.
• India: India is upgrading its vaccine manufacturing capacity to support the production and use of inactivated vaccines for various diseases. Local manufacturers are aiming to provide low-cost vaccines and improve access in rural communities.
• Japan: Japan has recently introduced new inactivated vaccines for seasonal flu and other viral infections. The country is focusing on improving vaccine safety, effectiveness, and maintaining high manufacturing quality.

Features of the Global Inactivated Vaccine Market

Market Size Estimates: Inactivated vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Inactivated vaccine market size by type, end use, and region in terms of value ($B).

Regional Analysis: Inactivated vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, end uses, and regions for the inactivated vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the inactivated vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the inactivated vaccine market by type (viral, bacterial, and others), end use (hospitals, homecare, specialty clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Inactivated Vaccine Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Inactivated Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Inactivated Vaccine Market by Type
  • 3.3.1: Viral
  • 3.3.2: Bacterial
  • 3.3.3: others
• 3.4: Global Inactivated Vaccine Market by End Use
  • 3.4.1: Hospitals
  • 3.4.2: Homecare
  • 3.4.3: Specialty Clinics
  • 3.4.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Inactivated Vaccine Market by Region
• 4.2: North American Inactivated Vaccine Market
  • 4.2.1: North American Market by Type: Viral, Bacterial, and others
  • 4.2.2: North American Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
• 4.3: European Inactivated Vaccine Market
  • 4.3.1: European Market by Type: Viral, Bacterial, and others
  • 4.3.2: European Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
• 4.4: APAC Inactivated Vaccine Market
  • 4.4.1: APAC Market by Type: Viral, Bacterial, and others
  • 4.4.2: APAC Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
• 4.5: ROW Inactivated Vaccine Market
  • 4.5.1: ROW Market by Type: Viral, Bacterial, and others
  • 4.5.2: ROW Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Inactivated Vaccine Market by Type
  • 6.1.2: Growth Opportunities for the Global Inactivated Vaccine Market by End Use
  • 6.1.3: Growth Opportunities for the Global Inactivated Vaccine Market by Region
• 6.2: Emerging Trends in the Global Inactivated Vaccine Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Inactivated Vaccine Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Inactivated Vaccine Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Pfizer
• 7.2: Sanofi
• 7.3: GlaxoSmithKline
• 7.4: Merck
• 7.5: AstraZeneca
• 7.6: Johnson & Johnson
• 7.7: CSL Behring